StockMacro
Menu

Krystal Biotech

$308.89 +2.1% in 6 monthsMarket cap $9.2B

KRYS on XNAS, Health Care, Krystal Biotech, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 26% to $470M while insiders sold $18M and 10% of shares are sold short.

  • GoodNet income rose 13% to $225.2M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
295
Website
krystalbio.com
Listed
Nasdaq, US
Last results
2 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $127.3M, net income $63.1M.
Quarter to 31 Dec 2021: revenue –, net income -$21.8MQuarter to 31 Mar 2022: revenue –, net income -$50.0MQuarter to 30 Jun 2022: revenue –, net income -$28.1MQuarter to 30 Sep 2022: revenue $0, net income -$29.9MQuarter to 30 Sep 2022: revenue $0, net income -$29.9MQuarter to 31 Dec 2022: revenue $0, net income -$32.1MQuarter to 31 Dec 2022: revenue $0, net income -$32.1MQuarter to 31 Mar 2023: revenue $0, net income -$45.3MQuarter to 31 Mar 2023: revenue $0, net income -$45.3MQuarter to 30 Jun 2023: revenue $0, net income -$33.2MQuarter to 30 Jun 2023: revenue $0, net income -$33.2MQuarter to 30 Sep 2023: revenue $8.6M, net income $80.7MQuarter to 30 Sep 2023: revenue $8.6M, net income $80.7MQuarter to 31 Dec 2023: revenue $42.1M, net income $8.7MQuarter to 31 Dec 2023: revenue $42.1M, net income $8.7MQuarter to 31 Mar 2024: revenue $45.2M, net income $932KQuarter to 31 Mar 2024: revenue $45.2M, net income $932KQuarter to 30 Jun 2024: revenue $70.3M, net income $15.6MQuarter to 30 Jun 2024: revenue $70.3M, net income $15.6MQuarter to 30 Sep 2024: revenue $83.8M, net income $27.2MQuarter to 30 Sep 2024: revenue $83.8M, net income $27.2MQuarter to 31 Dec 2024: revenue $91.1M, net income $45.5MQuarter to 31 Dec 2024: revenue $91.1M, net income $45.5MQuarter to 31 Mar 2025: revenue $88.2M, net income $35.7MQuarter to 31 Mar 2025: revenue $88.2M, net income $35.7MQuarter to 30 Jun 2025: revenue $96.0M, net income $38.3MQuarter to 30 Jun 2025: revenue $96.0M, net income $38.3MQuarter to 30 Sep 2025: revenue $97.8M, net income $79.4MQuarter to 30 Sep 2025: revenue $97.8M, net income $79.4MQuarter to 31 Dec 2025: revenue $107.1M, net income $51.4MQuarter to 31 Dec 2025: revenue $107.1M, net income $51.4MQuarter to 31 Mar 2026: revenue $116.4M, net income $55.9MQuarter to 31 Mar 2026: revenue $116.4M, net income $55.9MQuarter to 30 Jun 2026: revenue $119.2M, net income $54.8MQuarter to 30 Jun 2026: revenue $119.2M, net income $54.8MQuarter to 30 Sep 2026: revenue $127.3M, net income $63.1MQuarter to 30 Sep 2026: revenue $127.3M, net income $63.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $127.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$127.3M$63.1M
30 Jun 2026$119.2M$54.8M
31 Mar 2026$116.4M$55.9M
31 Dec 2025$107.1M$51.4M
30 Sep 2025$97.8M$79.4M
30 Jun 2025$96.0M$38.3M
31 Mar 2025$88.2M$35.7M
31 Dec 2024$91.1M$45.5M
30 Sep 2024$83.8M$27.2M
30 Jun 2024$70.3M$15.6M
31 Mar 2024$45.2M$932K
31 Dec 2023$42.1M$8.7M
30 Sep 2023$8.6M$80.7M
30 Jun 2023$0-$33.2M
31 Mar 2023$0-$45.3M
31 Dec 2022$0-$32.1M
30 Sep 2022$0-$29.9M
30 Jun 2022–-$28.1M
31 Mar 2022–-$50.0M
31 Dec 2021–-$21.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $470.0M $373.2M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +26% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $225.2M $198.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $7.37 $6.68
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 48.4% 42.4% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 47.9% 53.3% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 17.5% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $310.1M $165.6M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $911.9M $731.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$911.9M (net cash) -$731.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $48.44
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 40.7 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 19.5 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 17.5 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Krystal BiotechKRYS (this company) $9.2B40.719.5+26%47.9%
VaxcytePCVX $8.8Bloss–––
Kymera TherapeuticsKYMR $9.8Bloss96.3+134%-342%
Halozyme TherapeuticsHALO $10.4B21.55.8+45%26.9%
RepligenRGEN $10.5Bloss13.0+14%-1.5%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$18.0M

bought $0, sold $18.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.5%

440 13F filers vs 417

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

29.0M shares held by 13F filers (30 Sep 2026) of 29.6M outstanding (28 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

10%

3.0M shares sold short (30 Oct 2026) of 29.6M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

12.2

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.7%

2.9M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

83%

83% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 75%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+30%

$127.3M vs $97.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-42%

$996K vs $1.7M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 4.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.6×

25 articles in the last 7 days; its usual week has 4.5.

Price $308.89 on 20 Nov 2026, +51% over 12 months (12-month range $204.22 to $378.15)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $105.3M in the last 12 months (the 12 months before: -$49.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $127.3M in the latest quarter, +30% on a year earlier.
Capital spending per quarter. Capital spending $996K in the latest quarter, -42% on a year earlier.
Institutional holders (13F filers). 440 13F filers reported holding it in the latest 13F quarter, +61% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
23 Dec 20258-K and other filingsDirector or officer change
23 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 6.2M vs usual 1.5M (2025-03-31); 4.9x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 50 vs usual 20.50 (2024-09-30); 3.3x the same period a year earlier
5 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 83.8M vs usual 4.3M (2024-09-30); 9.8x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 3.7M vs usual 2.2M (2024-08-30); 2.5x the same period a year earlier
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 44 vs usual 18 (2024-06-30); 1.2x the same period a year earlier
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 70.3M vs usual 0 (2024-06-30)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 57 vs usual 17.50 (2024-03-31); 3.8x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.2M (2023-11-30); 1.8x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.2M (2023-11-15); 1.7x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.2M (2023-10-31); 1.6x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 1.2M (2023-10-13); 1.5x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 1.2M (2023-09-29); 1.5x the same period a year earlier
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 36 vs usual 16 (2023-06-30); 2.0x the same period a year earlier
7 Aug 20238-K and other filingsDirector or officer change
7 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Mar 20238-K and other filingsDirector or officer change
6 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Aug 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 16.5M vs usual 4.1M (2022-06-30); 4.1x the same period a year earlier
26 May 20228-K and other filingsChanged its auditor
10 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 17.2M vs usual 3.2M (2022-03-31); 7.0x the same period a year earlier
28 Feb 20228-K and other filingsDirector or officer change
15 Feb 2022Sharp changeMany funds opening a new position: many funds opening a new position, 33 vs usual 12 (2021-12-31); 2.1x the same period a year earlier
18 Jan 20228-K and other filingsDirector or officer change
18 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Dec 2021Sharp changeShort interest spike: short interest spike, 2.2M vs usual 1.3M (2021-11-30); 1.6x the same period a year earlier
30 Nov 2021Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.3M (2021-11-15); 1.4x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$14.1M published
Month from 1 Aug 2022: -$8.1M published
Month from 1 Nov 2022: -$287K published
Month from 1 Dec 2022: -$3.4M published
Month from 1 Jan 2023: -$12.4M published
Month from 1 Mar 2023: -$3.3M published
Month from 1 Apr 2023: -$9.5M published
Month from 1 May 2023: -$11.7M published
Month from 1 Jun 2023: -$19.6M published
Month from 1 Sep 2023: -$12.7M published
Month from 1 Dec 2023: -$10.6M published
Month from 1 Jan 2024: -$325K published
Month from 1 Feb 2024: -$1.1M published
Month from 1 Mar 2024: -$19.1M published
Month from 1 May 2024: -$3.3M published
Month from 1 Jun 2024: -$17.6M published
Month from 1 Sep 2024: -$19.8M published
Month from 1 Dec 2024: -$16.5M published
Month from 1 Mar 2025: -$17.9M published
Month from 1 Jul 2025: -$15.0M published
Month from 1 Dec 2025: -$22.0M published
Month from 1 Feb 2026: -$24.5M published
Month from 1 Mar 2026: -$16.6M published
Month from 1 May 2026: -$194K published
Month from 1 Jun 2026: -$15.8M published
Month from 1 Aug 2026: -$8.2M published
Month from 1 Sep 2026: -$18.0M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Apr 2026: 2 published
Revenue per quarter
Quarter ended 30 Sep 2022: $0; public on 7 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 27 Feb 2024
Quarter ended 31 Mar 2023: $0; public on 7 May 2024
Quarter ended 30 Jun 2023: $0; public on 6 Aug 2024
Quarter ended 30 Sep 2023: $8.6M; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $42.1M; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $45.2M; public on 7 May 2024
Quarter ended 30 Jun 2024: $70.3M; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $83.8M, +880% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $91.1M, +116% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $88.2M, +95% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $96.0M, +37% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $97.8M, +17% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $107.1M, +18% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $116.4M, +32% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $119.2M, +24% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $127.3M, +30% on a year earlier; public on 3 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $17.2M, +595% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $16.5M, +314% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $14.1M, -33% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $5.2M; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $5.4M, -69% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $2.8M, -83% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $1.8M, -87% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $1.8M, -65% on a year earlier; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $1.3M, -77% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $1.1M, -59% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $1.0M, -41% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $801K, -57% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $6.2M, +392% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.9M, +68% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $1.7M, +63% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $2.1M, +167% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $7.1M, +15% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $3.6M, +87% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $996K, -42% on a year earlier; public on 3 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 132; public on 14 Feb 2022
31 Mar 2022 report: 127; public on 16 May 2022
30 Jun 2022 report: 130; public on 15 Aug 2022
30 Sep 2022 report: 138; public on 14 Nov 2022
31 Dec 2022 report: 148; public on 14 Feb 2023
31 Mar 2023 report: 152; public on 15 May 2023
30 Jun 2023 report: 172; public on 14 Aug 2023
30 Sep 2023 report: 175; public on 14 Nov 2023
31 Dec 2023 report: 186; public on 14 Feb 2024
31 Mar 2024 report: 220; public on 15 May 2024
30 Jun 2024 report: 231; public on 14 Aug 2024
30 Sep 2024 report: 267; public on 14 Nov 2024
31 Dec 2024 report: 255; public on 14 Feb 2025
31 Mar 2025 report: 285; public on 15 May 2025
30 Jun 2025 report: 261; public on 14 Aug 2025
30 Sep 2025 report: 274; public on 14 Nov 2025
31 Dec 2025 report: 322; public on 17 Feb 2026
31 Mar 2026 report: 356; public on 15 May 2026
30 Jun 2026 report: 417; public on 14 Aug 2026
30 Sep 2026 report: 440; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 440 (30 Sep 2026), 1.7× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $105.3M in the last 12 months (the 12 months before: -$49.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $127.3M in the latest quarter, +30% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 85 insider trades

Last 90 days: 2 sales, $18.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
4 Sep 2026Krish S KrishnanPresident and CEOSellplanned in advance (10b5-1)25,000$359.32$9.0MForm 4
4 Sep 2026Suma KrishnanPresident, R&DSellplanned in advance (10b5-1)25,000$359.32$9.0MForm 4
14 Aug 2026Dino A RossiDirectorSell25,000$329.12$8.2MForm 4
26 Jun 2026John Charles ThomasEVP, General CounselSellplanned in advance (10b5-1); after exercising options1,000$347.27$347KForm 4
5 Jun 2026Krish S KrishnanPresident and CEOSellplanned in advance (10b5-1)25,000$308.12$7.7MForm 4
5 Jun 2026Suma KrishnanPresident, R&DSellplanned in advance (10b5-1)25,000$308.12$7.7MForm 4
27 May 2026John Charles ThomasEVP, General CounselSellplanned in advance (10b5-1)642$302.03$194KForm 4
6 Mar 2026Suma KrishnanPresident, R&DSellplanned in advance (10b5-1)25,000$263.21$6.6MForm 4

440 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 72 opened a position, 49 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)4.4M15.0%$1.5B+22K+0.5%
BlackRock, Inc.3.6M12.1%$1.2B-591K-14%
Avoro Capital Advisors LLC2.9M9.75%$960.7MNo change
State Street Corp1.4M4.79%$472.3M+69K+5.1%
Vanguard Portfolio Management LLC1.3M4.34%$428.0M-288K-18%
Vanguard Capital Management LLC1.2M4.04%$398.0M-44K-3.5%
Soleus Capital Management, L.P.1.1M3.85%$379.0M+200K+21%
Geode Capital Management, LLC812K2.74%$270.0M+113K+16%
Capital World Investors779K2.63%$259.2M+1,421+0.2%
Hood River Capital Management LLC672K2.27%$223.5M+8,610+1.3%

Company events

All 28 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Dec 2025Director or officer change8-K
7 Aug 2023Director or officer change8-K
22 May 2023Signed a major agreementSame filing: sold shares privately8-K
8 May 2023Signed a major agreement8-K
6 Mar 2023Director or officer change8-K
26 May 2022Changed its auditor8-K
28 Feb 2022Director or officer change8-K
18 Jan 2022Director or officer change8-K

The 5 newest of 202 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Nov 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Krystal Biotech (KRYS): reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 5 Nov 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M2024-09-30: $83.8M
The quarter ended 30 Sep 2024 against the 8 quarters before it. this quarterearliernormal: $4.3M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 5 Nov 2024

Krystal Biotech reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.

This period
$83.8M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.3M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+12.5
Same quarter last year
$8.6M
History used
731 days
2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M2024-09-30: $83.8M
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

Krystal Biotech saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.

This period
50 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
5.5
How far from its usual level
+3.6
Same quarter last year
15
History used
2,557 days
2022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 442024-09-30: 50
the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

20 Aug 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Krystal Biotech (KRYS): reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year; it also saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year; and it had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year. Three unrelated kinds of activity within 42 days.

  • Financials: Quarterly revenue change, became public on 6 Aug 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
  • Short interest and volume: Short interest spike, became public on 12 Sep 2024
2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M
The quarter ended 30 Jun 2024 against the 7 quarters before it. this quarterearliernormal: $0
See the evidence (3 changes)

Financials: Quarterly revenue change became public on 6 Aug 2024

Krystal Biotech reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.

This period
$70.3M (the quarter ended 30 Jun 2024)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+70.3
Same quarter last year
$0
History used
639 days
2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M
the quarter ended 30 Jun 20247 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

Krystal Biotech saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
18
Typical spread (median absolute deviation)
3
How far from its usual level
+5.8
Same quarter last year
36
History used
2,465 days
2022-06-30: 182022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 44
the quarter ended 30 Jun 20248 earlier quartersnormal: 18

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 12 Sep 2024

Krystal Biotech had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.

This period
3.7M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
261K
How far from its usual level
+3.9
Same report last year
1.5M
History used
2,436 days
2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M2023-11-15: 2.1M2023-11-30: 2.1M2023-12-15: 1.9M2023-12-29: 2.2M2024-01-12: 2.0M2024-01-31: 2.0M2024-02-15: 2.5M2024-02-29: 2.5M2024-03-15: 2.2M2024-03-28: 2.2M2024-04-15: 2.4M2024-04-30: 2.6M2024-05-15: 2.8M2024-05-31: 2.7M2024-06-14: 2.9M2024-06-28: 3.5M2024-07-15: 3.7M2024-07-31: 3.5M2024-08-15: 3.5M2024-08-30: 3.7M
the 30 Aug 2024 report24 earlier reportsnormal: 2.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Nov 2021confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Krystal Biotech (KRYS): spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year, while it had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year. Two unrelated kinds of activity within 35 days.

  • Financials: Quarterly capital spending jump, became public on 9 Nov 2021
  • Short interest and volume: Short interest spike, became public on 10 Nov 2021
  • Short interest and volume: Short interest spike, became public on 25 Nov 2021
  • Short interest and volume: Short interest spike, became public on 10 Dec 2021
2019-09-30: $1.2M2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M
The quarter ended 30 Sep 2021 against the 8 quarters before it. this quarterearliernormal: $2.4M
See the evidence (4 changes)

Financials: Quarterly capital spending jump became public on 9 Nov 2021

Krystal Biotech spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.

This period
$21.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$1.0M
How far from its usual level
+12.1
Same quarter last year
$4.2M
History used
1,734 days
2019-09-30: $1.2M2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M
the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Nov 2021

Krystal Biotech had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.

This period
1.8M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+3.6
Same report last year
1.5M
History used
1,400 days
2020-10-30: 1.5M2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M
the 29 Oct 2021 report24 earlier reportsnormal: 1.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Nov 2021

Krystal Biotech had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.

This period
2.1M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+5.1
Same report last year
1.4M
History used
1,417 days
2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M
the 15 Nov 2021 report24 earlier reportsnormal: 1.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2021

Krystal Biotech had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.

This period
2.2M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
106K
How far from its usual level
+6.0
Same report last year
1.4M
History used
1,432 days
2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M2021-11-30: 2.2M
the 30 Nov 2021 report24 earlier reportsnormal: 1.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 23 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 23 Dec 2025Filings record

    Director or officer change

  3. 8 May 2025Financials change

    spent $6.2M on capital projects in the quarter ended 31 Mar 2025, 4.9× the same quarter last year.

    Same quarter last year: $1.3M; its normal quarter is $1.5M.

    See the evidence
    This period
    $6.2M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $1.5M
    Typical spread (median absolute deviation)
    $432K
    How far from its usual level
    +4.7
    Same quarter last year
    $1.3M
    History used
    3,012 days
    2023-03-31: $5.4M2023-06-30: $2.8M2023-09-30: $1.8M2023-12-31: $1.8M2024-03-31: $1.3M2024-06-30: $1.1M2024-09-30: $1.0M2024-12-31: $801K2025-03-31: $6.2M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $1.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 19 Nov 2024several at once

    reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year, while it saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 5 Nov 2024

    Krystal Biotech reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.

    This period
    $83.8M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $4.3M
    Typical spread (median absolute deviation)
    $4.3M
    How far from its usual level
    +12.5
    Same quarter last year
    $8.6M
    History used
    731 days
    2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M2024-09-30: $83.8M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

    Krystal Biotech saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.

    This period
    50 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    20.5
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +3.6
    Same quarter last year
    15
    History used
    2,557 days
    2022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 442024-09-30: 50
    the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  5. 14 Nov 2024Institutional holdings change

    saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 3.3× the same quarter last year.

    Same quarter last year: 15; its normal quarter is 20.5.

    See the evidence
    This period
    50 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    20.5
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +3.6
    Same quarter last year
    15
    History used
    2,557 days
    2022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 442024-09-30: 50
    the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 5 Nov 2024Financials change

    reported revenue of $83.8M for the quarter ended 30 Sep 2024, 9.8× the same quarter last year.

    Same quarter last year: $8.6M; its normal quarter is $4.3M.

    See the evidence
    This period
    $83.8M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $4.3M
    Typical spread (median absolute deviation)
    $4.3M
    How far from its usual level
    +12.5
    Same quarter last year
    $8.6M
    History used
    731 days
    2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M2024-09-30: $83.8M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $4.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 12 Sep 2024Short interest and volume change

    had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.

    Same report last year: 1.5M; its normal report is 2.2M.

    See the evidence
    This period
    3.7M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +3.9
    Same report last year
    1.5M
    History used
    2,436 days
    2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M2023-11-15: 2.1M2023-11-30: 2.1M2023-12-15: 1.9M2023-12-29: 2.2M2024-01-12: 2.0M2024-01-31: 2.0M2024-02-15: 2.5M2024-02-29: 2.5M2024-03-15: 2.2M2024-03-28: 2.2M2024-04-15: 2.4M2024-04-30: 2.6M2024-05-15: 2.8M2024-05-31: 2.7M2024-06-14: 2.9M2024-06-28: 3.5M2024-07-15: 3.7M2024-07-31: 3.5M2024-08-15: 3.5M2024-08-30: 3.7M
    the 30 Aug 2024 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 20 Aug 2024several at once

    reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year; it also saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year; and it had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year. Three unrelated kinds of activity within 42 days.

    See the evidence (3 changes)

    Financials: Quarterly revenue change became public on 6 Aug 2024

    Krystal Biotech reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.

    This period
    $70.3M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 7 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +70.3
    Same quarter last year
    $0
    History used
    639 days
    2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M
    the quarter ended 30 Jun 20247 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

    Krystal Biotech saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

    This period
    44 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    18
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +5.8
    Same quarter last year
    36
    History used
    2,465 days
    2022-06-30: 182022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 44
    the quarter ended 30 Jun 20248 earlier quartersnormal: 18

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 12 Sep 2024

    Krystal Biotech had 3.7M shares sold short in the 30 Aug 2024 report, 2.5× the same report last year.

    This period
    3.7M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +3.9
    Same report last year
    1.5M
    History used
    2,436 days
    2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M2023-11-15: 2.1M2023-11-30: 2.1M2023-12-15: 1.9M2023-12-29: 2.2M2024-01-12: 2.0M2024-01-31: 2.0M2024-02-15: 2.5M2024-02-29: 2.5M2024-03-15: 2.2M2024-03-28: 2.2M2024-04-15: 2.4M2024-04-30: 2.6M2024-05-15: 2.8M2024-05-31: 2.7M2024-06-14: 2.9M2024-06-28: 3.5M2024-07-15: 3.7M2024-07-31: 3.5M2024-08-15: 3.5M2024-08-30: 3.7M
    the 30 Aug 2024 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  9. 14 Aug 2024Institutional holdings change

    saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 1.2× the same quarter last year.

    Same quarter last year: 36; its normal quarter is 18.

    See the evidence
    This period
    44 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    18
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +5.8
    Same quarter last year
    36
    History used
    2,465 days
    2022-06-30: 182022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 572024-06-30: 44
    the quarter ended 30 Jun 20248 earlier quartersnormal: 18

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 6 Aug 2024Financials change

    reported revenue of $70.3M for the quarter ended 30 Jun 2024, against none in the same quarter last year.

    See the evidence
    This period
    $70.3M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 7 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +70.3
    Same quarter last year
    $0
    History used
    639 days
    2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $8.6M2023-12-31: $42.1M2024-03-31: $45.2M2024-06-30: $70.3M
    the quarter ended 30 Jun 20247 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 15 May 2024Institutional holdings change

    saw 57 13F filers open a new position in the quarter ended 31 Mar 2024, 3.8× the same quarter last year.

    Same quarter last year: 15; its normal quarter is 17.5.

    See the evidence
    This period
    57 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    17.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +10.7
    Same quarter last year
    15
    History used
    2,374 days
    2022-03-31: 152022-06-30: 182022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 362023-09-30: 152023-12-31: 232024-03-31: 57
    the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 12 Dec 2023Short interest and volume change

    had 2.1M shares sold short in the 30 Nov 2023 report, 1.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    2.1M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +5.3
    Same report last year
    1.2M
    History used
    2,162 days
    2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 988K2023-01-13: 1.1M2023-01-31: 1.0M2023-02-15: 1.1M2023-02-28: 1.2M2023-03-15: 1.1M2023-03-31: 1.2M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.1M2023-05-31: 1.2M2023-06-15: 1.3M2023-06-30: 1.4M2023-07-14: 1.4M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M2023-11-15: 2.1M2023-11-30: 2.1M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 28 Nov 2023Short interest and volume change

    had 2.1M shares sold short in the 15 Nov 2023 report, 1.7× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    2.1M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    103K
    How far from its usual level
    +5.5
    Same report last year
    1.2M
    History used
    2,147 days
    2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 988K2023-01-13: 1.1M2023-01-31: 1.0M2023-02-15: 1.1M2023-02-28: 1.2M2023-03-15: 1.1M2023-03-31: 1.2M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.1M2023-05-31: 1.2M2023-06-15: 1.3M2023-06-30: 1.4M2023-07-14: 1.4M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M2023-11-15: 2.1M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 10 Nov 2023Short interest and volume change

    had 2.1M shares sold short in the 31 Oct 2023 report, 1.6× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    2.1M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    99K
    How far from its usual level
    +6.0
    Same report last year
    1.3M
    History used
    2,132 days
    2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 988K2023-01-13: 1.1M2023-01-31: 1.0M2023-02-15: 1.1M2023-02-28: 1.2M2023-03-15: 1.1M2023-03-31: 1.2M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.1M2023-05-31: 1.2M2023-06-15: 1.3M2023-06-30: 1.4M2023-07-14: 1.4M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.1M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 25 Oct 2023Short interest and volume change

    had 2.0M shares sold short in the 13 Oct 2023 report, 1.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    2.0M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    90K
    How far from its usual level
    +5.5
    Same report last year
    1.3M
    History used
    2,114 days
    2022-10-14: 1.3M2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 988K2023-01-13: 1.1M2023-01-31: 1.0M2023-02-15: 1.1M2023-02-28: 1.2M2023-03-15: 1.1M2023-03-31: 1.2M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.1M2023-05-31: 1.2M2023-06-15: 1.3M2023-06-30: 1.4M2023-07-14: 1.4M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M2023-10-13: 2.0M
    the 13 Oct 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 12 Oct 2023Short interest and volume change

    had 2.0M shares sold short in the 29 Sep 2023 report, 1.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    2.0M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    85K
    How far from its usual level
    +5.9
    Same report last year
    1.3M
    History used
    2,100 days
    2022-09-30: 1.3M2022-10-14: 1.3M2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 988K2023-01-13: 1.1M2023-01-31: 1.0M2023-02-15: 1.1M2023-02-28: 1.2M2023-03-15: 1.1M2023-03-31: 1.2M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.1M2023-05-31: 1.2M2023-06-15: 1.3M2023-06-30: 1.4M2023-07-14: 1.4M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 1.5M2023-09-15: 1.6M2023-09-29: 2.0M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 14 Aug 2023Institutional holdings change

    saw 36 13F filers open a new position in the quarter ended 30 Jun 2023, 2.0× the same quarter last year.

    Same quarter last year: 18; its normal quarter is 16.

    See the evidence
    This period
    36 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    16
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +6.7
    Same quarter last year
    18
    History used
    2,099 days
    2021-06-30: 112021-09-30: 112021-12-31: 332022-03-31: 152022-06-30: 182022-09-30: 182022-12-31: 172023-03-31: 152023-06-30: 36
    the quarter ended 30 Jun 20238 earlier quartersnormal: 16

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  18. 7 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 7 Aug 2023Filings record

    Director or officer change

  20. 6 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 6 Mar 2023Filings record

    Director or officer change

  22. 9 Aug 2022Financials change

    spent $16.5M on capital projects in the quarter ended 30 Jun 2022, 4.1× the same quarter last year.

    Same quarter last year: $4.0M; its normal quarter is $4.1M.

    See the evidence
    This period
    $16.5M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $4.1M
    Typical spread (median absolute deviation)
    $2.4M
    How far from its usual level
    +3.6
    Same quarter last year
    $4.0M
    History used
    2,007 days
    2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M2022-03-31: $17.2M2022-06-30: $16.5M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $4.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 26 May 2022Filings record

    Changed its auditor

  24. 10 May 2022Financials change

    spent $17.2M on capital projects in the quarter ended 31 Mar 2022, 7.0× the same quarter last year.

    Same quarter last year: $2.5M; its normal quarter is $3.2M.

    See the evidence
    This period
    $17.2M (the quarter ended 31 Mar 2022)
    Normal quarter (median of 8 earlier)
    $3.2M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +8.4
    Same quarter last year
    $2.5M
    History used
    1,916 days
    2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M2022-03-31: $17.2M
    the quarter ended 31 Mar 20228 earlier quartersnormal: $3.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 28 Feb 2022Filings record

    Director or officer change

  26. 14 Feb 2022Institutional holdings change

    saw 33 13F filers open a new position in the quarter ended 31 Dec 2021, 2.1× the same quarter last year.

    Same quarter last year: 16; its normal quarter is 12.

    See the evidence
    This period
    33 (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    12
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.0
    Same quarter last year
    16
    History used
    1,553 days
    2019-12-31: 112020-03-31: 132020-06-30: 302020-09-30: 52020-12-31: 162021-03-31: 152021-06-30: 112021-09-30: 112021-12-31: 33
    the quarter ended 31 Dec 20218 earlier quartersnormal: 12

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  27. 18 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 18 Jan 2022Filings record

    Director or officer change

  29. 10 Dec 2021Short interest and volume change

    had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.

    Same report last year: 1.4M; its normal report is 1.3M.

    See the evidence
    This period
    2.2M (the 30 Nov 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +6.0
    Same report last year
    1.4M
    History used
    1,432 days
    2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M2021-11-30: 2.2M
    the 30 Nov 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 25 Nov 2021Short interest and volume change

    had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.

    Same report last year: 1.4M; its normal report is 1.3M.

    See the evidence
    This period
    2.1M (the 15 Nov 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +5.1
    Same report last year
    1.4M
    History used
    1,417 days
    2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M
    the 15 Nov 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 16 Nov 2021several at once

    spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year, while it had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year. Two unrelated kinds of activity within 35 days.

    See the evidence (4 changes)

    Financials: Quarterly capital spending jump became public on 9 Nov 2021

    Krystal Biotech spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.

    This period
    $21.0M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $2.4M
    Typical spread (median absolute deviation)
    $1.0M
    How far from its usual level
    +12.1
    Same quarter last year
    $4.2M
    History used
    1,734 days
    2019-09-30: $1.2M2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 10 Nov 2021

    Krystal Biotech had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.

    This period
    1.8M (the 29 Oct 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +3.6
    Same report last year
    1.5M
    History used
    1,400 days
    2020-10-30: 1.5M2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M
    the 29 Oct 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Nov 2021

    Krystal Biotech had 2.1M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.

    This period
    2.1M (the 15 Nov 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +5.1
    Same report last year
    1.4M
    History used
    1,417 days
    2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M
    the 15 Nov 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2021

    Krystal Biotech had 2.2M shares sold short in the 30 Nov 2021 report, 1.6× the same report last year.

    This period
    2.2M (the 30 Nov 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +6.0
    Same report last year
    1.4M
    History used
    1,432 days
    2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M2021-11-15: 2.1M2021-11-30: 2.2M
    the 30 Nov 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  32. 10 Nov 2021Short interest and volume change

    had 1.8M shares sold short in the 29 Oct 2021 report, 1.2× the same report last year.

    Same report last year: 1.5M; its normal report is 1.3M.

    See the evidence
    This period
    1.8M (the 29 Oct 2021 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +3.6
    Same report last year
    1.5M
    History used
    1,400 days
    2020-10-30: 1.5M2020-11-13: 1.4M2020-11-30: 1.4M2020-12-15: 1.3M2020-12-31: 1.4M2021-01-15: 1.3M2021-01-29: 1.2M2021-02-12: 1.1M2021-02-26: 1.2M2021-03-15: 1.2M2021-03-31: 1.2M2021-04-15: 1.2M2021-04-30: 1.2M2021-05-14: 1.2M2021-05-28: 1.2M2021-06-15: 1.2M2021-06-30: 1.1M2021-07-15: 1.1M2021-07-30: 1.3M2021-08-13: 1.4M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.5M2021-10-15: 1.7M2021-10-29: 1.8M
    the 29 Oct 2021 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 9 Nov 2021Financials change

    spent $21.0M on capital projects in the quarter ended 30 Sep 2021, 5.0× the same quarter last year.

    Same quarter last year: $4.2M; its normal quarter is $2.4M.

    See the evidence
    This period
    $21.0M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $2.4M
    Typical spread (median absolute deviation)
    $1.0M
    How far from its usual level
    +12.1
    Same quarter last year
    $4.2M
    History used
    1,734 days
    2019-09-30: $1.2M2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M2021-03-31: $2.5M2021-06-30: $4.0M2021-09-30: $21.0M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $2.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  34. 2 Mar 2021Financials change

    spent $7.2M on capital projects in the quarter ended 31 Dec 2020, 3.2× the same quarter last year.

    Same quarter last year: $2.3M; its normal quarter is $1.6M.

    See the evidence
    This period
    $7.2M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $1.6M
    Typical spread (median absolute deviation)
    $354K
    How far from its usual level
    +5.6
    Same quarter last year
    $2.3M
    History used
    1,461 days
    2018-12-31: $1.3M2019-03-31: $1.7M2019-06-30: $1.2M2019-09-30: $1.2M2019-12-31: $2.3M2020-03-31: $1.5M2020-06-30: $1.9M2020-09-30: $4.2M2020-12-31: $7.2M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $1.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 4 Jan 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 4 Jan 2021Filings record

    Director or officer change

  37. 5 May 2020Filings record

    Director or officer change

  38. 25 Feb 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 25 Feb 2020Filings record

    Director or officer change

  40. 27 Nov 2019Short interest and volume change

    had 2.0M shares sold short in the 15 Nov 2019 report, 12× the same report last year.

    Same report last year: 174K; its normal report is 580K.

    See the evidence
    This period
    2.0M (the 15 Nov 2019 report)
    Normal report (median of 24 earlier)
    580K
    Typical spread (median absolute deviation)
    269K
    How far from its usual level
    +3.7
    Same report last year
    174K
    History used
    686 days
    2018-11-15: 174K2018-11-30: 183K2018-12-14: 163K2018-12-31: 246K2019-01-15: 300K2019-01-31: 325K2019-02-15: 376K2019-02-28: 417K2019-03-15: 557K2019-03-29: 716K2019-04-15: 583K2019-04-30: 576K2019-05-15: 524K2019-05-31: 577K2019-06-14: 653K2019-06-28: 624K2019-07-15: 839K2019-07-31: 1.0M2019-08-15: 1.1M2019-08-30: 1.2M2019-09-13: 1.2M2019-09-30: 1.4M2019-10-15: 1.7M2019-10-31: 1.9M2019-11-15: 2.0M
    the 15 Nov 2019 report24 earlier reportsnormal: 580K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 59 entries; narrow the window or the kind of data to see older ones.

Not listed: 170 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001711279
Ticker
KRYS
Domain
krystalbio.com
Employer name
KRYSTAL BIOTECH, INC. (1 unverified)
Hq location
PA|PITTSBURGH|15203 (1 unverified)
Name
a4q25krysex211.htm, Document, EX-21.1, Krystal Biotech, Inc.
Uei
H5VRRQJHRBL3
Wikidata
Q124665205
  • DOL H-1B labor condition applications and PERM certifications32 data points16 Mar 2020 to 23 Feb 2026
  • SEC Form 13F institutional holdings333 data points30 Sep 2017 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)109 records18 Aug 2017 to 2 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)610 data points30 Sep 2016 to 28 Oct 2026
  • SEC Form 4 insider transactions85 records, 216 data points25 Sep 2017 to 4 Sep 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026